Abstract
Steviol glycoside (SG), derived from Stevia rebaudiana leaves, is the third-largest global source of sweetener. However, its lingering bitterness and metallic aftertaste limit its applications. Enzymatic glycosylation of natural SGs is a promising approach for resolving this flavor-related issue. Herein, a novel mono β-1,6-glycosylated rebaudioside D (Reb D) derivative Reb M8 was selectively produced from Reb D using glycosyltransferase UGT94E13 from Gardenia jasminoides. Next, the sweetness and bioactivity of inhibitory effects of this derivative on the inflammatory factor tumor necrosis factor-alpha (TNF-α), involved in various diseases, were primarily studied. Electronic tongue analysis indicated that the construction of a β-1,6-glucoside bond at the C-13 position of Reb D improved sweetness. Furthermore, Reb M8 exhibited inhibitory effects on TNF-α, implying its potential application in the treatment of various diseases. Overall, this study presents a selective method for producing a new SG Reb M8 with improved sweetness and the ability to inhibit TNF-α, which makes it a promising candidate for several applications in food and pharmaceutical industries.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
